Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LY3532226 · 4 trials · 4 indications
A summary of TEAEs and SAEs, regardless of causality, will be reported in the Reported Adverse Events module
A summary of TEAEs and SAEs, regardless of causality, will be reported in the Reported Adverse Events module
A summary of TEAEs and SAEs, regardless of causality, will be reported in the Reported Adverse Events module
PD: AUC60-120min of plasma glucagon during the insulin-induced hypoglycemia
Change from Baseline in Total cDI
A summary of SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module
| Arm | Type | Description |
|---|---|---|
| LY3532226 (Part A) | EXPERIMENTAL | LY3532226 administered subcutaneously (SC) |
| Placebo (Part A) | PLACEBO_COMPARATOR | Placebo administered SC |
| LY3532226 (Part B) | EXPERIMENTAL | LY3532226 administered SC |
| Placebo (Part B) | PLACEBO_COMPARATOR | Placebo administered SC |
| LY3532226 (Part C) | EXPERIMENTAL | LY3532226 administered SC |
| Placebo (Part C) | PLACEBO_COMPARATOR | Placebo administered SC |
| LY3532226 | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| LY3532226 + Dulaglutide (Part A) | EXPERIMENTAL | LY3532226 administered subcutaneously (SC) followed by dulaglutide administered SC. |
| Placebo + Dulaglutide (Part A) | PLACEBO_COMPARATOR | Placebo administered SC followed by dulaglutide administered SC. |
| Dulaglutide + Placebo (Part B) | ACTIVE_COMPARATOR | Dulaglutide administered SC in combination with placebo given SC. |
| LY3532226 + Dulaglutide (Part B) | EXPERIMENTAL | LY3532226 administered SC in combination with Dulaglutide given SC. |
| LY3532226 + Placebo (Part B) | EXPERIMENTAL | LY3532226 administered SC in combination with placebo given SC. |
| Name | Type | Description |
|---|---|---|
| LY3532226 | DRUG | Administered SC |
| Placebo | DRUG | Administered SC |
| Dulaglutide | DRUG | Administered SC. |
Inclusion Criteria: * Have a body weight not exceeding 150 kilograms (kg) or 330 pounds (lb) and body mass index (BMI) within the range of 30 to 40 kilogram per square meter (kg/m²) * Have had a stable body weight that is less than or equal to 5% change in body weight for 3 months prior to screenin...
LY3532226 is an investigational small molecule being studied for metabolic conditions including obesity, type 2 diabetes mellitus, and type 1 diabetes mellitus. It has been evaluated in Phase 1 clinical trials in healthy participants and in participants with these conditions. The drug is not approved and remains in clinical development.
LY3532226 is being developed by Eli Lilly and Company, a pharmaceutical company traded on the NYSE under the ticker LLY. The company has sponsored Phase 1 clinical trials of LY3532226 across multiple countries including the United States, Singapore, and Germany.
LY3532226 is in Phase 1 clinical development. All four clinical trials listed for LY3532226 are Phase 1 studies and have been completed. The drug is investigational and has not been approved by regulatory authorities for any indication.
LY3532226 has completed four Phase 1 trials: NCT04923269 in healthy participants in Singapore, NCT05407961 in type 2 diabetes participants in Germany, NCT05887999 in type 1 diabetes participants in the United States, and NCT06557356 in participants with obesity in the United States and Singapore.
No alternative names for LY3532226 have been disclosed. The drug is identified solely by its investigational code LY3532226 in clinical trial registrations. It is a small molecule being studied for metabolic indications including obesity and diabetes.